Zacks: Brokerages Anticipate Myovant Sciences Ltd (NYSE:MYOV) to Post -$0.80 EPS

Brokerages forecast that Myovant Sciences Ltd (NYSE:MYOV) will report ($0.80) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Myovant Sciences’ earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.73). Myovant Sciences reported earnings of ($0.99) per share during the same quarter last year, which would suggest a positive year over year growth rate of 19.2%. The firm is expected to issue its next quarterly earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($3.14) per share for the current financial year, with EPS estimates ranging from ($3.44) to ($2.92). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.75) per share, with EPS estimates ranging from ($3.03) to ($2.52). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Myovant Sciences.

MYOV has been the topic of a number of recent analyst reports. Svb Leerink initiated coverage on Myovant Sciences in a research report on Monday, August 19th. They set an “outperform” rating and a $26.00 price target on the stock. ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Goldman Sachs Group set a $18.00 price target on Myovant Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Zacks Investment Research downgraded Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Finally, Cowen reissued a “buy” rating on shares of Myovant Sciences in a research report on Friday, September 6th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $21.89.

Several large investors have recently modified their holdings of MYOV. Janus Henderson Group PLC boosted its holdings in shares of Myovant Sciences by 73.6% during the second quarter. Janus Henderson Group PLC now owns 4,350,335 shares of the company’s stock worth $39,371,000 after acquiring an additional 1,843,943 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Myovant Sciences by 169.8% during the second quarter. Victory Capital Management Inc. now owns 2,272,013 shares of the company’s stock worth $20,562,000 after acquiring an additional 1,429,770 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Myovant Sciences during the second quarter worth approximately $7,733,000. First Manhattan Co. boosted its holdings in shares of Myovant Sciences by 2,146.6% during the second quarter. First Manhattan Co. now owns 400,000 shares of the company’s stock worth $3,620,000 after acquiring an additional 382,195 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Myovant Sciences by 33.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,086,893 shares of the company’s stock worth $9,836,000 after acquiring an additional 274,745 shares during the period. Institutional investors own 40.45% of the company’s stock.

NYSE MYOV traded down $0.33 during trading on Friday, reaching $5.53. 200,561 shares of the company’s stock were exchanged, compared to its average volume of 259,714. The business has a 50 day moving average price of $5.16 and a 200-day moving average price of $8.69. The stock has a market capitalization of $511.74 million, a P/E ratio of -1.35 and a beta of 0.91. The company has a debt-to-equity ratio of 1.24, a current ratio of 3.42 and a quick ratio of 3.42. Myovant Sciences has a fifty-two week low of $4.14 and a fifty-two week high of $26.02.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.